# papulopustular rosacea FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/papulopustular-rosacea

> 2 upcoming FDA catalysts in papulopustular rosacea: Rhapsido® (remibrutinib, NVS) on Dec 2027 to Mar 2028 (topline data readout); Rhapsido® (remibrutinib, NVS) on December 2027 (primary completion).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| November 4, 2024 | [Emrosi (DFD-29) FDA approval](https://sec-api.dev/pdufa/dfd-29) | DERM | papulopustular rosacea | completed, approved | "Emrosi™ was approved by the FDA in November 2024." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1867066/000110465926034506/tm269707d1_ex99-1.htm)) |
| Dec 2027 to Mar 2028 | [Rhapsido® (remibrutinib) topline data readout](https://sec-api.dev/pdufa/remibrutinib) | NVS | Papulopustular Rosacea | scheduled | "NCT07681271 (A Phase 2 Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Patients With Papulopustular Rosacea (PPR)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-12-07 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07681271)) |
| December 2027 | [Rhapsido® (remibrutinib) primary completion](https://sec-api.dev/pdufa/remibrutinib) | NVS | Papulopustular Rosacea | scheduled | "NCT07681271 (A Phase 2 Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Patients With Papulopustular Rosacea (PPR)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-12-07 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07681271)) |

## Drugs

- [Emrosi (DFD-29)](https://sec-api.dev/pdufa/dfd-29) (DERM)
- [Rhapsido® (remibrutinib)](https://sec-api.dev/pdufa/remibrutinib) (NVS)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/papulopustular-rosacea.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "papulopustular rosacea FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/papulopustular-rosacea

```bibtex
@misc{secapidev_indications_papulopustular_rosacea_20261116,
  title        = {papulopustular rosacea FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/papulopustular-rosacea}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_papulopustular_rosacea_20261116","title":"papulopustular rosacea FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/papulopustular-rosacea","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
